Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.

Publication Type:

Journal Article


Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 27, Issue 25, p.4204-10 (2009)


2009, Antineoplastic Agents, Australia, Clinical Research Division, Drug Resistance, Neoplasm, Europe, Fusion Proteins, bcr-abl, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Leukemic, Humans, Korea, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Mutation, Piperazines, Protein Kinase Inhibitors, Pyrimidines, Time Factors, Treatment Outcome, United States


Nilotinib is a second-generation tyrosine kinase inhibitor indicated for the treatment of patients with chronic myeloid leukemia (CML) in chronic phase (CP; CML-CP) and accelerated phase (AP; CML-AP) who are resistant to or intolerant of prior imatinib therapy. In this subanalysis of a phase II study of nilotinib in patients with imatinib-resistant or imatinib-intolerant CML-CP, the occurrence and impact of baseline and newly detectable BCR-ABL mutations were assessed.